{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:54Z","timestamp":1786119414459,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,15]]},"DOI":"10.1097\/tp.0b013e3181bc2583","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T03:19:13Z","timestamp":1257218353000},"page":"1131-1136","source":"Crossref","is-referenced-by-count":33,"title":["Initial Liver Involvement in Acute GVHD is Predictive for Nonrelapse Mortality"],"prefix":"10.1097","volume":"88","author":[{"given":"Marie","family":"Robin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Porcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Peffault","family":"de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ribaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Petropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Devergie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210211","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"R2-13-20210211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings.","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"key":"R3-13-20210211","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00007890-199102000-00034","article-title":"Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.","volume":"51","author":"Beatty","year":"1991","journal-title":"Transplantation"},{"key":"R4-13-20210211","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2008.17.6545","article-title":"Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.","volume":"26","author":"Hahn","year":"2008","journal-title":"J Clin Oncol"},{"key":"R5-13-20210211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"R6-13-20210211","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade.","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"R7-13-20210211","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2006-01-0254","article-title":"An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.","volume":"108","author":"Leisenring","year":"2006","journal-title":"Blood"},{"key":"R8-13-20210211","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","article-title":"Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome.","volume":"75","author":"Weisdorf","year":"1990","journal-title":"Blood"},{"key":"R9-13-20210211","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment.","volume":"76","author":"Martin","year":"1990","journal-title":"Blood"},{"key":"R10-13-20210211","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R11-13-20210211","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2006-07-034348","article-title":"Hyperacute GVHD: Risk factors, outcomes, and clinical implications.","volume":"109","author":"Saliba","year":"2007","journal-title":"Blood"},{"key":"R12-13-20210211","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks.","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"R13-13-20210211","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1083-8791(03)00162-9","article-title":"Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review.","volume":"9","author":"Weisdorf","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-13-20210211","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","article-title":"Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"key":"R15-13-20210211","first-page":"939","article-title":"Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.","volume":"90","author":"Lee","year":"2005","journal-title":"Haematologica"},{"key":"R16-13-20210211","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hep.20529","article-title":"Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation.","volume":"41","author":"Gooley","year":"2005","journal-title":"Hepatology"},{"key":"R17-13-20210211","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2007-09-112987","article-title":"Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.","volume":"111","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"R18-13-20210211","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"R19-13-20210211","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bmt.1705313","article-title":"Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.","volume":"37","author":"Sohn","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R20-13-20210211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems.","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-13-20210211","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","article-title":"Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10\/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-13-20210211","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.","volume":"113","author":"Ringden","year":"2009","journal-title":"Blood"},{"key":"R23-13-20210211","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2008.18.7740","article-title":"HLA-identical sibling compared with 8\/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.","volume":"27","author":"Arora","year":"2009","journal-title":"J Clin Oncol"},{"key":"R24-13-20210211","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.2004.07.130","article-title":"Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission.","volume":"22","author":"Kiehl","year":"2004","journal-title":"J Clin Oncol"},{"key":"R25-13-20210211","first-page":"57","article-title":"A randomized prospective multicenter phase III trial comparing standard GvHD prophylaxis with cyclosporine and methotrexate with additional pretransplant ATG Fresenius (ATG-F) in allogeneic stem cell transplantation from matched unrelated donors.","volume":"112","author":"Finke","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R26-13-20210211","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 Randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200911150-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:06:03Z","timestamp":1786039563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200911150-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,15]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181bc2583","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11,15]]}}}